hhw
And the climate certainly does care about cumulative CO2.
Would have, could have, should have. But didn't. Trying to hold others accountable without getting one's own house in order just comes off as the blatant hypocrisy it actually is. Until we do better ourselves, we are in no position to call others out.
https://www.worldometers.info/co2-emissions/co2-emissions-pe...
https://www.carbonbrief.org/analysis-which-countries-are-his....
*A long, long time ago, I looked at about 1000 co-location customers' MRTG stats and compared their monthly 95th percentile Mbps to their average sustained data transfer in GB, and something like 90% of them were between 150GB-250GB per Mb and 98% of them were between 180GB-220GB. Many people assume 324GB which would require their traffic to be perfectly flatlined throughout the month, which obviously rarely ever happens.
To be fair, big tech despite their massive volume pay much higher rates than small networks because the carriers charge them enough to fully cover their costs to build out their networKs, while they make all their profits from selling their excess capacity to the little guys for pennies on the dollar.
There are huge promotions multiple times a year because the competition is fierce between the top providers. When long-term contracts that subsidized phones were still around up to a few years ago, the buyouts to switch providers were so aggressive that you could end up with an extra few hundred dollars in your pocket on top of a new phone every 2 years when switching providers, or staying with the same provider and getting the loyalty/retention department to match offers. Yes, there may be better deals to be found down south sometimes, but not by enough of a margin to deal with cross-border banking, currency conversion, and much worse consumer protection laws for most people.
Yes, additional competition might potentially help drive prices down, but the low ROI on the huge amount of infrastructure required for such a small population might also result in worse economies of scale for all players resulting in the need to cut corners on coverage or service quality to remain competitive.
Also, I'm not convinced coverage is better down south. Anecdotally, I seem to hit way more deadspots driving down I5 through Washington and Oregon than I do on Highway 1 across BC to Alberta despite having much larger swathes of populated areas. I'm also shocked everytime I go to New York and get zero cell signal in every subway station including near Wall Street, when every underground transit station in Vancouver has coverage (admittedly Toronto does not have this though).
Although this type of knowledge and expertise is rather specialized, we are able to focus on these specific areas without getting involved in the intricacies of the downstream side of our clients' networks, thus avoiding the need for us to have too much client specific or institutional knowledge. This has worked out very well with the handful of eyeball networks we're currently working with in the Pacific Northwest, and we intend to more actively extend this line of business down the coast in the near future.
Maybe other factors like culture matter more than tipping?
My understanding is that another side effect of HCQ is that it extends the QT cycle, and given the duress COVID-19 puts on the heart, there is not an insignificant risk of cardiak arrest. There may not be as much data to show this as conclusively or prevalently as some might like, but the underlying mechanisms are well enough understood that it would be reckless to continue prescribing HCQ until it had been sufficiently demonstrated that the benefits outweighed this risk.
There really wasn't sufficient reason to think that HCQ would work in the first place, based on any understanding of how the drugs works. It was just the original, now discredited paper from China that opened up the floodgates in the first place. The antiviral properties are far too weak and would require far too high (dangerous) concentrations in vivo, far in excess of what's commonly prescribed for other purposes, to match the earlier in vitro results. If there's any benefit to HCQ, it would be from immunosupression. But dexamethasone serves that purpose much more effectively, and has shown much better results so it doesn't make much sense to continue exploring HCQ.
This paper you've cited supposedly showing positive results is a preprint and has not been published yet, which suggests it hasn't satisfied the peer review process in whichever journal it is intended to be published in. The study was also suspended partway through so it's unlikely it'll ever be completed. I don't entirely disagree that science is a pure numbers game (only papers that stand up to peer review, not only from the journal but from the wider scientific community are worth consideration), but you're undermining your own argument with this poor selection of a paper. If it does eventually end up published, and doesn't have too many glaring issues with its methodology pointed out (some of which are already indicated in the comments on medrxiv), it may be worth mentioning in the future but it certainly isn't right now. And the existence of this paper doesn't make the site's analysis any less dishonest. Suggesting 100% of papers of some particularly category when only one (in actuality none) exist is clearly wrong, and intentionally misleading if not dishonest.
I also don't entirely agree that numbers don't matter. Given a set of papers that are published, properly peer reviewed, and don't have any glaring issues with their methodology, it certainly matters if the vast majority demonstrate something while a tiny number suggest something else. This would indicate that tiny number are outliers, and may have had some problems that weren't immediately obvious. Otherwise, their results would have been reproducable which is a key indication of the validity of their empirical data.
There are also other, better studies that show negative results or no benefit. Why did you pick this particular one?
Note that the only RCT with positive results is https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v...
Which was late, not early. Meanwhile, quickly searching through all the RCT's listed, there's 5 that are negative and 10 that were inconclusive (i.e. showed no benefit).
So there's 15 to 1 against the effectiveness of HCQ using the highest standard of study (RCT's), yet somehow that site attempts to represent that as 100% of 'early' RCT's showing positive results.
https://respectfulinsolence.com/2020/04/03/zelenko-smith-aba...
In vitro results are much less meaningful than in vivo results. It can be a useful early validation step, but is far from telling us anything about real world efficacy.
There's enough in vivo studies at this point that in vitro studies should no longer be part of the conversation.
That's very different than making a specific claim that you already have a feature right now, that you in fact don't. That claim cannot possibly be made in good faith, as it's currently outright false, and you can never retroactively apply end to end encryption on conversations that have already happened.
It also hasn't been used to anywhere near the same frequency.
https://www.nytimes.com/2019/07/28/world/americas/brazil-def...
I'm not aware of the US mandating lines be resold at controlled costs dictated by the FCC, but I don't deal with consumer/eyeball networks so perhaps I'm missing something? From the frequent complaints I see about duopolies in most US networks, I'm quite skeptical of this.
In metro Vancouver, I'm able to purchase 1G VPLS fiber links for around $800/mo, and dark fiber in the $1000-$2000/mo range for the most part, with similar pricing in Calgary and Toronto. Quotes I've seen in Seattle and Los Angeles have been typically 3-6x that range.
I can purchase municipal dark fiber in Coquitlam or New Westminster (suburbs of Vancouver) for $400/mo, and I believe Montreal is $500/mo. I'm not aware of being able to buy metro dark fiber for anywhere near that anywhere in the US.